Colorectal Cancer Serum
Powered by BiozAbout:Colorectal Cancer Serum from consented donors with confirmed colorectal cancer, processed and frozen within 24 hours of collection. Supports CEA and CA 19-9 tumour marker assay work, systemic inflammatory and cytokine profiling, tumour immunology research across MSI-high and MMR-proficient disease, and serum proteomics. Donors can be stratified by stage, tumour sidedness, MSI/MMR and RAS/BRAF status, and treatment, with matched healthy controls available.
About Colorectal Cancer Serum
Colorectal Cancer Serum for Tumour Immunology and Oncology Biomarker Research
Our Colorectal Cancer Serum is sourced from IRB-consented donors clinically diagnosed with colorectal cancer. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for oncology biomarker, tumour immunology and translational research. Colorectal cancer is a neoplastic disease that develops through progressive somatic genetic change in colonic epithelium rather than through immune self-recognition.
Why Serum for Colorectal Cancer Research
- Carcinoembryonic antigen (CEA) is the best-established circulating marker in colorectal cancer and is measured in serum. It is used for post-resection surveillance and treatment monitoring rather than for screening, and disease-state serum is essential for developing or benchmarking CEA and CA 19-9 assays.
- Most colorectal cancers follow the adenoma-carcinoma sequence with sequential APC/WNT, KRAS and TP53 alteration. A distinct subset is mismatch repair deficient and microsatellite instability high; these tumours are heavily lymphocyte-infiltrated and respond to immune checkpoint blockade, so dMMR/MSI-H versus proficient tumours give very different soluble immune profiles.
- RAS and BRAF mutation status determines eligibility for anti-EGFR antibody therapy, and matched serum from genotyped donors supports work on circulating correlates of targeted-therapy response.
- Serum captures the systemic inflammatory host response to tumour burden, including CRP, IL-6 and neutrophil-related indices that carry prognostic weight in colorectal cancer independent of stage.
- Serum is the matrix on which most commercial tumour marker and autoantibody-panel immunoassays are validated, making it the practical choice for head-to-head assay comparison work.
- For circulating tumour DNA and methylation-based approaches, plasma is generally the preferred matrix; matched colorectal cancer plasma from the same donors can be requested alongside serum.
Donor Stratification Available
- Stage at diagnosis and localised versus metastatic disease
- Primary tumour location, including right-sided versus left-sided and rectal disease
- Molecular status where documented: MSI/MMR status, KRAS, NRAS and BRAF mutation status
- Treatment status: treatment-naive, post-resection, fluoropyrimidine-based chemotherapy, anti-EGFR antibody, anti-VEGF antibody, or immune checkpoint inhibitor
- Family history and hereditary syndrome context where documented, including Lynch syndrome
- Matched healthy controls available, including screening-age controls with normal colonoscopy where documented
Product Features
- Collected from clinically confirmed colorectal cancer donors
- Research Use Only (RUO)
- Processed and frozen within 24 hours of collection
- IRB-approved protocols with documented consent
- Standard and custom aliquot volumes; volumes reported per lot
- Matched plasma, whole blood, PBMC and leukopak from the same donors available on request
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported medical history and comorbidities
- Stage, tumour location and treatment details available on request
Applications
- CEA and CA 19-9 tumour marker assay development and validation
- Serum cytokine, chemokine and soluble immune checkpoint profiling
- Biomarker discovery for early detection, prognosis and recurrence surveillance
- Tumour immunology research comparing MSI-high and MMR-proficient disease
- Serum proteomics, glycoproteomics and metabolomics
- Autoantibody and tumour-associated antigen panel development
- Therapeutic candidate screening and treatment-response biomarker validation
- Disease-state control matrix for oncology immunoassay qualification
Other Colorectal Cancer Specimen Types
- Colorectal Cancer Plasma
- Colorectal Cancer Whole Blood
- Colorectal Cancer PBMC
- Colorectal Cancer Leukopak
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Colorectal cancer serum is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human serum page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), Serum
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Serum are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Colorectal Cancer Serum with normal donor samples for comparison
Healthy Serum
102 In Stock View InventoryNeed a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.